MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)

DIAGNOSTIC_TEST4 trials

Sponsors

Centre Hospitalier Universitaire Dijon, Elisa Giannetta, First Affiliated Hospital of Zhejiang University, Children's Hospital of Philadelphia

Conditions

Diffusion MRIFRDAFriedreich's AtaxiaProstate CancerSarcopenic ObesityType 2 Diabetes

Phase 4

Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism

TerminatedNCT02721888

Centre Hospitalier Universitaire DijonType 2 Diabetes

Start: 2012-07-10Updated: 2026-02-06

Unknown Phase

Validation of an Algorithm for the Diagnosis of Sarcopenic Obesity

RecruitingNCT06815978

Elisa GiannettaSarcopenic Obesity

Start: 2024-05-24End: 2027-03-01Target: 150Updated: 2025-02-10

MR Microstructural Imaging for Prostate Cancer Diagnosis

RecruitingNCT07249281

First Affiliated Hospital of Zhejiang UniversityDiffusion MRI, Prostate Cancer

Start: 2020-09-01End: 2028-12-31Target: 2000Updated: 2025-11-25

GABA and GSH in FRDA

Enrolling by invitationNCT07635030

Children's Hospital of PhiladelphiaFRDA, Friedreich's Ataxia

Start: 2024-05-08End: 2030-06-01Target: 60Updated: 2026-06-09

Related Papers

Liraglutide reduces plasma dihydroceramide levels in patients with type 2 diabetes.

2023-05-0420 citations

Liraglutide Reduces Postprandial Hyperlipidemia by Increasing ApoB48 (Apolipoprotein B48) Catabolism and by Reducing ApoB48 Production in Patients With Type 2 Diabetes Mellitus

Arteriosclerosis Thrombosis and Vascular Biology2018-07-1964 citations